EP
CAI

Essential Partners’s Caris Life Sciences CAI Stock Holding History

Essential Partners’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26K Buy
71
+38
+115% +$680 ﹤0.01% 2142
2026
Q1 		$590 Buy
+33
New +$721 ﹤0.01% 2385

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's CAI Position: Q2 2026 in Review

Essential Partners increased its Caris Life Sciences (CAI) stake by 115% in Q2 2026, buying an estimated $680 and bringing the position to 71 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #2142.

Essential Partners first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Essential Partners held 71 shares of Caris Life Sciences worth $1.26K as of Q2 2026.
  • Essential Partners bought 38 Caris Life Sciences shares in Q2 2026, an estimated $680.
  • Caris Life Sciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2142 holding.
  • Essential Partners first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.